Relapsed/Refractory Diffuse Large B-Cell Lymphoma Study

 

Phase: 2/3

Status: Ongoing

About

A Phase 2/3 Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma


Details

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

Sponsor: Karyopharm Therapeutics Inc

NCT04442022